Qlife  has been committed to the development <br />of clinical mass spectrometry industry Qlife  has been committed to the development <br />of clinical mass spectrometry industry
Understand Qlife
Qlife has been committed to the development
of clinical mass spectrometry industry

Promote industry innovation, serve precision medicine, benefit human health, and innovation for quality life .

 
 Company Profile
Jiangsu Qlife Medical Technology Group Co., LTD.

Jiangsu Qlife Medical Technology Group Co., LTD. ("Qlife "") is a high-tech company in the field of precision medicine. Centered on mass spectrometry technology and driven by multi-omics research, we pioneer the innovation in developing diagnostics for the healthcare industry. We provide the leading total solution of clinical mass spectrometry, including omics research, mass spectrometry instruments, IVD reagents, and ICL services. We are the leader of multi-omics research translation and clinical mass spectrometry technology development for precision medicine in China.

 

As a technology driven company, Qlife has developed an internationally leading research platform of proteomics and metabolomics that can support untargeted and targeted clinical omics research as well as new biomarker discovery, and verification and translation of innovative clinical applications. At present, the company offers the testing of more than 500 clinical mass spectrometry analytes, covering maternal and neonatal health, endocrinological, cardiovascular, tumor, neurological, and Therapeutics Drug Monitoring, including numerous original precision omics assays, leading the development of China's clinical mass spectrometry market.

 

Qlife has established subsidiaries or branches in Nanjing, Shanghai, Beijing, Wuhan, Hangzhou, Fuzhou, Xi'an and other places, including R&D centers, medical device factories and independent clinical laboratories, and has built a nationwide sales and service network. With excellent technical strength and robust service system, Qlife has established in-depth cooperation with dozens of benchmark hospitals in China, and its products and services have been widely acclaimed through verification of industry KOLs.

 

The expertise and focus of Qlife has been widely recognized by the investment community, and has received multiple rounds of investments by IDG Capital, Centurium Capital, Cowin Capital, Yang Zi Investment Group and other famous venture capital investors.

 

Hoping to let precision medicine benefit everyone, Qlife will continue to focus on applying multi-omics technology to precision medicine, and is committed to developing the clinical mass spectrometry industry, promoting innovation, serving precision medicine, benefiting human health, and improving quality of life. "

 
Brand Culture
  • Corporate mission
    Corporate mission
    Innovation for Quality Life
  • Core values
    Core values
    Sincerity and dedication
    Innovation and excellence
    Confident and committed
    Cooperation for win-win
    Result-driven
 
Development history
2013
  • In October 2013, Dr. Xiaoliang Cheng, founder of Qlife, received the R&D 100 Awards as one of the inventors of Qchip, the world's leading high-throughput mass spectrometry chip technology
2014
  • In June 2014, Dr. Xiaoliang Cheng and his team published a cover article on ACS Chemical Biology, a top international journal, focusing on the high-throughput mass spectrometry technlogy
2016
  • In July 2016, Qlife was registered and officially established
2017
  • In March 2017, Qlife's Fujian subsidiary was established in the Digital Fujian National Medical Big Data Industrial Park
  • In July 2017, Qlife received the angel round investment by IDG Capital
  • In October 2017, Qlife established a joint laboratory with the PLA General Hospital
  • In November 2017, Qlife established a joint laboratory with the Zhongshan Hospital in Shanghai
  • In December 2017, Qlife's Fujian subsidiary was granted the license of medical institute
2018
  • In March 2018, Academian Ge Junbo announced the research results of cooperation with Qlife at the 16th China Interventional Therapeutics (CIT2018) for the first time
  • In June 2018, Qlife established a joint laboratory with –the Wuhan Asia Heart Hospital
  • In August 2018, Qlife's factory in Fuzhou was granted the license for IVD reagent production
  • In October 2018, Qlife settled in the Jiangbei New Area as a key investment project of Nanjing
  • In December 2018, Qlife received the series A investment by IDG Capital, Yang Zi Investment Group and StarVC
2019
  • In March 2019, Qlife launched a full suite of clinical mass spectrometry testing products
  • In March 2019, Qlife established its factory in the Jiangbei New Area Intelligent Manufacturing Industrial Park
  • In May 2019, Qlife launched the Clinical Mass Spectrometry Research and Industry Alliance with KOLs and other and leading companies in the industry
  • In August 2019, Qlife's factory in Nanjing commenced operation
  • In December 2019, the mass spectrometer developed and produced by Qlife's factory in Nanjing completed the registration inspection of medical devices in Jiangsu Province
2020
  • In April 2020, Qlife Lab 9000 triple quadrupole mass spectrometer testing system was granted the Class-II registration for medical device
  • In May 2020, Qlife's GMP factory in Nanjing passed the system assessment and was granted the Class-II license for medical device production
  • In July 2020, Qlife's GMP factory in Nanjing was certified to meet the dual international quality system of ISO 13485 and ISO 9001
  • In September 2020, Qlife officially launched Qlife Lab 9000 series mass spectrometer at the Annual Conference of the Chinese Society of Laboratory Medicine
  • In December 2020, Qlife received the series A+ investment led by IDG Capital and Yang Zi Investment Group
2021
  • In May 2021, the first Class-II IVD kit of Qlife was approved, and several class II IVD kits were in the process of being registered
  • In July 2021, Qlife's Nanjing Clinical Laboratory obtained the certificate of medical institute
  • In July 2021, Qlife's subsidiary Pinyi Intelligent Manufacturing was accredited as Nanjing's New Research and Development Institute
  • In August 2021, Qlife relocated its headquarters to the Jiangbei New District of Nanjing and was renamed Jiangsu Qlife Medical Technology Group Co., LTD
  • In August 2021, Qlife received the series B investment led by Centurium Capital and Cowin Capital
2013
2014
2016
2017
2018
2019
2020
2021
 
Honor and qualification

​​​版权所有©2017-2021 Qlife Lab 江苏品生医疗科技集团有限公司版权所有 苏ICP备2022008113号